Creating vaccines and biologics to combat infectious diseases
Official title: Task V09: Development and Manufacture of Toxoid Fusion Master Banks
Funded at Idt Biologika Gmbh · NIH-10701630 · Data updated 2026-11-12
This study is working on creating new vaccines to help protect people from infections like those caused by E. coli, so that patients can have better options for staying healthy and safe from serious diseases.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Idt Biologika Gmbh NIH-funded |
| Lab location | 1 site (Dessau-Rosslau, Germany) |
| Project start | May 15, 2018 |
| Project end | May 14, 2028 |
| Funding year | 2022 |
| Award (this year) | $587,861 |
| NIH project number | 272201800011I-P00002-759302000003-1 |
| Project ID | NIH-10701630 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals at risk for infections caused by E. coli and other emerging infectious diseases.
✕Less likely to help
Patients who are not at risk for infectious diseases or those who have already been vaccinated against the targeted pathogens may not receive benefit from this research.
What this research studies
This research focuses on the development and manufacturing of vaccines and biologics aimed at preventing infectious diseases, including those caused by E. coli. It involves planning, optimizing, and producing these products in compliance with regulatory standards for clinical trials. Patients may benefit from the introduction of new vaccines that could protect against serious infections and bioterrorism threats. The research also includes support for regulatory submissions to ensure safety and efficacy.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines that protect patients from infectious diseases.
How similar studies have gone: Other research has shown success in developing vaccines for infectious diseases using similar methodologies, indicating a promising approach.
Where this research is happening
-
Idt Biologika Gmbh
Dessau-Rosslau, Germany Active
Researchers
- Principal investigator: Neubert, Andreas — Idt Biologika Gmbh
- Study coordinator: Neubert, Andreas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.